227 related articles for article (PubMed ID: 16048942)
1. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients.
Seibel NL; Schwartz C; Arrieta A; Flynn P; Shad A; Albano E; Keirns J; Lau WM; Facklam DP; Buell DN; Walsh TJ
Antimicrob Agents Chemother; 2005 Aug; 49(8):3317-24. PubMed ID: 16048942
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants.
Heresi GP; Gerstmann DR; Reed MD; van den Anker JN; Blumer JL; Kovanda L; Keirns JJ; Buell DN; Kearns GL
Pediatr Infect Dis J; 2006 Dec; 25(12):1110-5. PubMed ID: 17133155
[TBL] [Abstract][Full Text] [Related]
3. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.
Groll AH; Mickiene D; Petraitis V; Petraitiene R; Ibrahim KH; Piscitelli SC; Bekersky I; Walsh TJ
Antimicrob Agents Chemother; 2001 Dec; 45(12):3322-7. PubMed ID: 11709303
[TBL] [Abstract][Full Text] [Related]
4. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
5. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.
Petraitis V; Petraitiene R; Groll AH; Roussillon K; Hemmings M; Lyman CA; Sein T; Bacher J; Bekersky I; Walsh TJ
Antimicrob Agents Chemother; 2002 Jun; 46(6):1857-69. PubMed ID: 12019101
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies.
Toubai T; Tanaka J; Ota S; Shigematsu A; Shono Y; Ibata M; Hashino S; Kondo T; Kakinoki Y; Masauzi N; Kasai M; Iwasaki H; Kurosawa M; Asaka M; Imamura M
Intern Med; 2007; 46(1):3-9. PubMed ID: 17202726
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
[TBL] [Abstract][Full Text] [Related]
8. Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections.
Tabata K; Katashima M; Kawamura A; Tanigawara Y; Sunagawa K
Biol Pharm Bull; 2006 Aug; 29(8):1706-11. PubMed ID: 16880629
[TBL] [Abstract][Full Text] [Related]
9. Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia.
Yanada M; Kiyoi H; Murata M; Suzuki M; Iwai M; Yokozawa T; Baba H; Emi N; Naoe T
Intern Med; 2006; 45(5):259-64. PubMed ID: 16595990
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.
Hiemenz J; Cagnoni P; Simpson D; Devine S; Chao N; Keirns J; Lau W; Facklam D; Buell D
Antimicrob Agents Chemother; 2005 Apr; 49(4):1331-6. PubMed ID: 15793107
[TBL] [Abstract][Full Text] [Related]
11. Micafungin (Mycamine) for fungal infections.
Med Lett Drugs Ther; 2005 Jun; 47(1211):51-2. PubMed ID: 15961968
[TBL] [Abstract][Full Text] [Related]
12. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation.
Sirohi B; Powles RL; Chopra R; Russell N; Byrne JL; Prentice HG; Potter M; Koblinger S
Bone Marrow Transplant; 2006 Jul; 38(1):47-51. PubMed ID: 16715107
[TBL] [Abstract][Full Text] [Related]
13. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.
Gumbo T; Drusano GL; Liu W; Kulawy RW; Fregeau C; Hsu V; Louie A
Antimicrob Agents Chemother; 2007 Mar; 51(3):968-74. PubMed ID: 17194830
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases.
Park JS; Kim DH; Choi CW; Jeong SH; Choi JH; Kim K; Kim SJ; Jung CW; Yang DH; Jang JH
Acta Haematol; 2010; 124(2):92-7. PubMed ID: 20664196
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic analysis of micafungin in Japanese patients with fungal infections.
Tabata K; Katashima M; Kawamura A; Kaibara A; Tanigawara Y
Drug Metab Pharmacokinet; 2006 Aug; 21(4):324-31. PubMed ID: 16946560
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan.
Kohno S; Masaoka T; Yamaguchi H; Mori T; Urabe A; Ito A; Niki Y; Ikemoto H
Scand J Infect Dis; 2004; 36(5):372-9. PubMed ID: 15287383
[TBL] [Abstract][Full Text] [Related]
17. Micafungin.
Carver PL
Ann Pharmacother; 2004 Oct; 38(10):1707-21. PubMed ID: 15340133
[TBL] [Abstract][Full Text] [Related]
18. [Why might micafungin be the drug of choice in pediatric patients?].
Ramos Amador JT; Prieto Tato L; Guillén Martín S
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():23-8. PubMed ID: 21420573
[TBL] [Abstract][Full Text] [Related]
19. Micafungin: a therapeutic review.
Higashiyama Y; Kohno S
Expert Rev Anti Infect Ther; 2004 Jun; 2(3):345-55. PubMed ID: 15482200
[TBL] [Abstract][Full Text] [Related]
20. Micafungin for empirical antifungal therapy in patients with febrile neutropenia: multicenter phase 2 study.
Mizuno H; Sawa M; Yanada M; Shirahata M; Watanabe M; Kato T; Nagai H; Ozawa Y; Morishita T; Tsuzuki M; Goto E; Tsujimura A; Suzuki R; Atsuta Y; Emi N; Naoe T
Int J Hematol; 2013 Aug; 98(2):231-6. PubMed ID: 23857638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
